Compare PHAR & SMWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHAR | SMWB |
|---|---|---|
| Founded | 1988 | 2007 |
| Country | Netherlands | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 793.4M | 778.8M |
| IPO Year | 2020 | 2021 |
| Metric | PHAR | SMWB |
|---|---|---|
| Price | $10.16 | $7.63 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 6 |
| Target Price | ★ $38.33 | $4.00 |
| AVG Volume (30 Days) | 33.8K | ★ 549.2K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.04 | $11.07 |
| Revenue Next Year | $2.51 | $11.17 |
| P/E Ratio | $3,041.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.62 | $2.22 |
| 52 Week High | $21.34 | $9.52 |
| Indicator | PHAR | SMWB |
|---|---|---|
| Relative Strength Index (RSI) | 38.04 | 40.68 |
| Support Level | $9.62 | $7.16 |
| Resistance Level | $11.60 | $9.03 |
| Average True Range (ATR) | 0.47 | 0.44 |
| MACD | -0.03 | -0.14 |
| Stochastic Oscillator | 9.45 | 20.54 |
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
Similarweb Ltd provides digital data and analytics that power critical business decisions. The group recognizes revenue from subscriptions to the platform and other subscription products on a straight-line basis over the term of the contract subscription period beginning on the date access to the platform is granted, provided all other revenue recognition criteria have been met. It has geographic presence in Israel, the United States, the United Kingdom, Asia Pacific, Europe, and Other. The group generates the majority of its revenue from the United States.